Surgical devices and technology provider Conmed Corporation (CNMD) recently announced plans to co-develop a sequence of educational programs along with Exactech, Inc. (EXAC). Exactech provides restoration products for bone and joint replacement. The co-developed academic program is designed to improve standards of care for patients across the spectrum of knee and shoulder repair.
Conmed and Exactech plan to utilize their positional advantage and expertise to enhance patient care. The exhaustive medical educational program covers arthroscopic intervention to complete joint replacement techniques and technologies. Development of quarterly itinerary for the academic program to be launched in early 2013 is underway.
Management at Conmed believes that the educational program will provide a top-notch experience to surgeons and practitioners in related fields. The company’s alliance with Exactech will help to develop a discursive approach to surgeon education and is expected to improve the technical skill-set of the surgeons. The goal of the program is to provide excellent educational experience to orthopaedic surgeons.
The companies understand the need for advanced techniques to treat the continuum of orthopaedic injuries and appropriate training of surgeons. Furthermore, there is a lack of medical programs to address injuries ranging from soft tissue damage to joint disease. Consequently, management at Exactech asserts that there should be a paradigm shift in orthopaedic educational programs.
The educational programs will be carried out at Conmed Linvatec’s exclusive Center for Orthopaedic Education based in Largo, Florida. Conmed Linvatec is a subsidiary of Conmed Corporation. The joint development of the academic program will also provide Conmed with an opportunity to exhibit its world-class training facility in Largo to leading surgeons.
Conmed serves the arthroscopy, endosurgery and electrosurgery market and produces cardiac disposables. It also offers various training programs for clinicians. This underlines its commitment towards enhanced patient care and improved clinical results. The company serves a highly competitive market along with larger and technically more proficient companies like Covidien Inc. (COV), Smith & Nephew plc. (SNN) and Stryker Corp. (SYK).
Conmed currently retains a Zacks #2 Rank, which translates into a short-term ‘Buy’ rating. We maintain our long-term ‘Neutral’ recommendation on the stock.Read the Full Research Report on SYK
More From Zacks.com